Prime Care Hospice, Llc 4225 West Glendale Avenue, Suite A-200, Phoenix, AZ, 85051 | |
(623) 847-2323 |
News Archive
A proposal to randomly drug test doctors and increase the limit on medical malpractice lawsuit awards also has a strong show of support in the poll.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
"Women in developing countries could play a major role in remedying the situation, if given the chance," Jeanette Brown, a scientist with the University of Connecticut in Storrs, said on Monday at the 244th National Meeting & Exposition of the American Chemical Society (ACS), an American Chemical Society press release reports.
Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.
› Verified 1 days ago
Name | Prime Care Hospice, Llc |
---|---|
Location | 4225 West Glendale Avenue, Suite A-200, Phoenix, Arizona |
Hospice ID | 031579 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
Accreditation Provider | Community Health Accreditation Partner (CHAP) |
SSA county code | 060 |
News Archive
A proposal to randomly drug test doctors and increase the limit on medical malpractice lawsuit awards also has a strong show of support in the poll.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
"Women in developing countries could play a major role in remedying the situation, if given the chance," Jeanette Brown, a scientist with the University of Connecticut in Storrs, said on Monday at the 244th National Meeting & Exposition of the American Chemical Society (ACS), an American Chemical Society press release reports.
Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.
› Verified 1 days ago
NPI Number | 1770769978 |
Organization Name | Prime Care Hospice, Llc |
Address | 4225 W Glendale Ave Ste A200 Phoenix, Arizona, 85051 |
Phone Number | (623)847-2323 |
News Archive
A proposal to randomly drug test doctors and increase the limit on medical malpractice lawsuit awards also has a strong show of support in the poll.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
"Women in developing countries could play a major role in remedying the situation, if given the chance," Jeanette Brown, a scientist with the University of Connecticut in Storrs, said on Monday at the 244th National Meeting & Exposition of the American Chemical Society (ACS), an American Chemical Society press release reports.
Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.
› Verified 1 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.3 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 95.6 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 98.9 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 47.3 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 99.4 | 97.3 |
Patients who got timely treatment for shortness of breath | 93.8 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 94.1 | 93.3 |
News Archive
A proposal to randomly drug test doctors and increase the limit on medical malpractice lawsuit awards also has a strong show of support in the poll.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
"Women in developing countries could play a major role in remedying the situation, if given the chance," Jeanette Brown, a scientist with the University of Connecticut in Storrs, said on Monday at the 244th National Meeting & Exposition of the American Chemical Society (ACS), an American Chemical Society press release reports.
Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.
› Verified 1 days ago
Home Health Aides | 7 |
Counselors | 1 |
Medical Social Workers | 1.5 |
Physicians | 2 |
Registered Nurses | 5 |
Other Personnel | 4 |
Total Employees | 20.5 |
---|
News Archive
A proposal to randomly drug test doctors and increase the limit on medical malpractice lawsuit awards also has a strong show of support in the poll.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
"Women in developing countries could play a major role in remedying the situation, if given the chance," Jeanette Brown, a scientist with the University of Connecticut in Storrs, said on Monday at the 244th National Meeting & Exposition of the American Chemical Society (ACS), an American Chemical Society press release reports.
Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.
› Verified 1 days ago
Others | 5 |
Total Volunteers | 5 |
---|
News Archive
A proposal to randomly drug test doctors and increase the limit on medical malpractice lawsuit awards also has a strong show of support in the poll.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
"Women in developing countries could play a major role in remedying the situation, if given the chance," Jeanette Brown, a scientist with the University of Connecticut in Storrs, said on Monday at the 244th National Meeting & Exposition of the American Chemical Society (ACS), an American Chemical Society press release reports.
Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.
› Verified 1 days ago
Hospice Of The Valley - Central Location: 1510 East Flower Street, Building 2, Phoenix, Arizona, 85014 Phone: (623) 847-2323 |
Banner Hospice Phoenix Office Location: 202 East Earll Drive, Suite 160, Phoenix, Arizona, 85012 Phone: (623) 847-2323 |
Valiant Hospice & Palliative Care, Llc Location: 67 East Weldon Avenue, Suite 317, Phoenix, Arizona, 85012 Phone: (623) 847-2323 |
Premier Hospice And Palliative Care, Llc Location: 4530 East Shea Boulevard, Suite 165, Phoenix, Arizona, 85028 Phone: (623) 847-2323 |